Get To Know Us

Steve St. Onge, PharmD, MBA

Steve St. Onge, PharmD, MBA

Chief Business Officer

Steve St. Onge, PharmD, MBA is a biotechnology executive with over 15 years of experience in corporate development, M&A, licensing, medical affairs and clinical practice.  Prior to joining Clarametyx in 2024, Dr. St. Onge led corporate development, licensing and corporate communications at Paratek Pharmaceuticals, playing a pivotal role in the achievement of multiple corporate milestones, including the approval and successful launch of NUZYRA® (omadacycline) and the company’s $462 million take-private transaction by Gurnet Point Capital and Novo Holdings in 2023.  Earlier in his career, Dr. St. Onge held roles of increasing responsibility in medical affairs and clinical research at Paratek, Tardis, and The Medicines Company.  Dr. St. Onge began his career as a critical care pharmacy specialist and maintains active faculty appointments in the department of anesthesia at Advent Health University and the University of Scranton.  Dr. St. Onge earned a Doctor of Pharmacy degree from the Albany College of Pharmacy and MBA from Endicott College.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.